Anti-CD3 MUC1 bispecific antibody - Benhealth Biopharmaceutical

Drug Profile

Anti-CD3 MUC1 bispecific antibody - Benhealth Biopharmaceutical

Alternative Names: Activated CIK-anti-CD3-MUC1 bispecific antibody - Benhealth; Anti-CD3-MUC1 bispecific antibody; Cytokine induced killer cell therapy - Benhealth; PD-1 inhibitor activated CIK; PD-1 inhibitor activated CIK cells - Benhealth; PD-1 inhibitor activated cytokine induced killer cell therapy

Latest Information Update: 20 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Benhealth Biopharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Cell therapies; Drug conjugates
  • Mechanism of Action CD3 antigen inhibitors; Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 12 Apr 2018 Phase-II clinical trials in Pancreatic cancer (Late-stage disease) in China (unspecified route) (NCT03509298)
  • 10 Apr 2018 Phase-II clinical trials in Renal cancer (Second-line therapy or greater, Late-stage disease) in China (unspecified route) (NCT03540199)
  • 05 Apr 2018 Phase-II clinical trials in Gastric cancer (Late-stage disease) in China (unspecified route) (NCT03554395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top